Phase 3 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been confirmed through a tissue test (biopsy) to have small cell lung cancer (SCLC)
- People whose cancer has not spread beyond the chest area (classified as Stage I to III, with no distant spread)
- People whose cancer can be measured on scans using a standard method called RECIST 1.1
- People aged 18 or older
- People who are reasonably well and able to carry out daily activities (assessed using a standard scale called ECOG, scoring 0, 1, or 2)
- People who have never had radiation treatment to the chest area before
- People who have given written agreement to participate in the trial
- People whose blood test results show the bone marrow is working well enough — including adequate levels of white blood cells, neutrophils, platelets, and haemoglobin
- People whose liver and kidney function tests are within acceptable ranges (confirm with trial site for exact values)
- People whose lungs are functioning above certain minimum levels on breathing tests (confirm with trial site for exact values)
Who may not be able to join:
- People who have previously had surgery or radiation treatment for any type of lung cancer
- People whose cancer has spread into fluid around the lungs or heart
- People with serious ongoing health conditions that are not well controlled, such as active infection or unstable heart disease
- People with medical, psychological, or social circumstances that may make it difficult to follow the trial requirements
- People who have another active cancer (exceptions may apply for certain low-risk cancers such as localised prostate or breast cancer, or a type of skin cancer called basal cell carcinoma — confirm with trial site)
- People who are unable or unwilling to give written agreement to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Iñigo San Miguel Arregui, MD PhD, Institute of Biomedical Research of Salamanca
Phone: +34 923291600
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.